Results 101 to 110 of about 16,388 (147)

Clinical effect of proprotein convertase subtilisin/kexin type 9 inhibition in patients undergoing coronary artery bypass surgery. [PDF]

JTCVS Open
Nasso G, Marchese A, Santarpino G, Vignaroli W, Calabrese V, Taverna G, Larosa C, Bartolomucci F, Fiore F, Brigiani MS, Contegiacomo G, Greco E, Speziale G.   +12 more
europepmc   +1 more source

PCSK9 inhibitors improve lipid profile and hepatic steatosis surrogate indicators in patients with MAFLD and type 2 diabetes. [PDF]

Front Med (Lausanne)
Zhou Q, Liu X, Tang Y, Pan C, Bi X.
europepmc   +1 more source

Dramatic Coronary Artery Aneurysm Regression After Coronary Artery Bypass Grafting and Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitor Therapy. [PDF]

Interdiscip Cardiovasc Thorac Surg
Yokoyama Y, Higashino H, Fujieda H, Abe M.   +3 more
europepmc   +1 more source

Lipid-Lowering Efficacy and Safety of Oral Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors: A Systematic Review and Meta-Analysis. [PDF]

Adv Ther
Masson W, Lobo M, Giunta G, Barbagelata L, Nogueira JP.   +4 more
europepmc   +1 more source

Methodological Challenges of Emulating a Target Trial to Assess Effectiveness of Timing of PCSK9 Inhibitor Treatment Initiation Post Myocardial Infarction. [PDF]

Pharmacoepidemiol Drug Saf
Cars T, Gustafsson S, Chan Q, Dhalwani N, Kent ST, Briggs A, Gale CP, Gitt A, Jukema JW, Steg PG, Sundström J, James S, Hagström E, Brookhart MA.   +13 more
europepmc   +1 more source

Mendelian randomization analysis of lipid-lowering drug targets and neuropsychiatric disorders. [PDF]

Medicine (Baltimore)
Peng S, Liu M, Du F, Li K.
europepmc   +1 more source

Assessing the Cost Effectiveness of an Incremental Lipid-Lowering Therapy Approach After Coronary Artery Bypass Grafting Using Nationwide Data. [PDF]

J Am Heart Assoc
Deo SV, Ciminata G, Mahalwar G, Salerno PRVO, McAllister DA, Elgudin YE, Orkaby A, Virani S, Fremes S, Rajagopalan S, Sattar N, Pell JP.   +11 more
europepmc   +1 more source

Obicetrapib and renal function: A welcome signal, but not yet a kidney story. [PDF]

Am J Prev Cardiol
Barkas F, Ray KK.
europepmc   +1 more source

Managing Progressive Atherosclerotic Cardiovascular Disease in a Patient with Elevated Lipoprotein(a). [PDF]

Anatol J Cardiol
Yurtseven E, Tokgözoğlu L.
europepmc   +1 more source

Proprotein Convertase Subtilisin/Kexin Type 9 Induces Platelet-Derived Transforming Growth Factor-<i>β</i> to Promote Myocardial Fibrosis After Myocardial Infarction. [PDF]

Hum Mutat
Wang Q, Huang W, Xia D, Wang F, Nair S.
europepmc   +1 more source